Xeris Biopharma Holdings, Inc./$XERS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Ticker
$XERS
Sector
Primary listing
Employees
394
Headquarters
Website
XERS Metrics
BasicAdvanced
$1.2B
-
-$0.10
0.92
-
Price and volume
Market cap
$1.2B
Beta
0.92
52-week high
$10.08
52-week low
$3.59
Average daily volume
2.7M
Financial strength
Current ratio
1.928
Quick ratio
1.251
Long term debt to equity
-29,205.575
Total debt to equity
-29,924.971
Interest coverage (TTM)
0.54%
Profitability
EBITDA (TTM)
28.036
Gross margin (TTM)
84.56%
Net profit margin (TTM)
-5.88%
Operating margin (TTM)
5.98%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
2.88%
Return on equity (TTM)
107.18%
Valuation
Price to revenue (TTM)
4.074
Price to book
-1,334.36
Price to tangible book (TTM)
-10.03
Price to free cash flow (TTM)
108.691
Free cash flow yield (TTM)
0.92%
Free cash flow per share (TTM)
0.064
Growth
Revenue change (TTM)
42.05%
Earnings per share change (TTM)
-76.18%
3-year revenue growth (CAGR)
39.26%
3-year earnings per share growth (CAGR)
-52.97%
XERS News
AllArticlesVideos
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Business Wire·1 month ago
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Business Wire·2 months ago
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xeris Biopharma Holdings, Inc. stock?
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $1.2B as of December 12, 2025.
What is the P/E ratio for Xeris Biopharma Holdings, Inc. stock?
The price to earnings (P/E) ratio for Xeris Biopharma Holdings, Inc. (XERS) stock is 0 as of December 12, 2025.
Does Xeris Biopharma Holdings, Inc. stock pay dividends?
No, Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders as of December 12, 2025.
When is the next Xeris Biopharma Holdings, Inc. dividend payment date?
Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.